drugset / Trial / NCT04156087
Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This phase-2 monocenter non-randomized prospective clinical trial evaluates the effectiveness of minimally invasive microwave ablation plus immunotherapy for unresectable non-metastatic locally advanced pancreatic cancer.
Timeline
- Start
- 2020-05-09
- Primary completion
- 2024-01-29
- Completion
- 2024-01-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | — |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Tremelimumab | Monoclonal antibody | 75 mg | — |